Most reflux products fight the wrong enemy. That’s why they don’t fix reflux.

When it comes to reflux, there’s no shortage of “fixes.” Antacids, H₂ blockers, PPIs — they all promise relief by going after acid. But acid isn’t the enemy.

The real issue is where the acid goes and why it keeps coming back. Here’s how each common approach stacks up — and where they fall short.

Traditional Treatments Focus on the Acid

Antacids (e.g., Tums®, Rolaids®):
Neutralize stomach acid temporarily, like putting water on a fire. Like drying off with a towel, but you’re still standing in the rain.

  • Problem: They wear off quickly, so symptoms return soon after. Overuse can cause imbalances in minerals such as magnesium and calcium, leading to constipation, kidney issues, or other health problems (Tytgat 2013).

H₂ Blockers (e.g., famotidine, cimetidine, nizatidine):
Reduce acid production moderately by blocking histamine receptors in the stomach.

  • Problem: They take longer to work than antacids and, with chronic use, can interfere with nutrient absorption (especially vitamin B₁₂, iron, and calcium) (Ito and Jensen 2010).

Proton Pump Inhibitors (PPIs, e.g., omeprazole, esomeprazole, lansoprazole):
Shut down stomach acid production almost completely.

  • Problem: Long-term use has been linked to nutrient deficiencies, increased risk of Clostridioides difficile infection, pneumonia, chronic kidney disease, and even bone fractures (Freedberg et al. 2017). Over time, PPIs may lose effectiveness, and discontinuation often triggers acid rebound hypersecretion, where symptoms return stronger than before (Scarpignato et al. 2016).
  • Problem: Chronic use of PPIs can cause physiologic changes in the stomach such as an increase in parietal cell count, which are the cells that make acid. (Morris et al. 2023). This change conditions the user to involuntary dependency upon the PPI, otherwise a very large and disproportionate amount of acid is secreted with meals, making reflux more severe if a dose is missed. Morris, N., Nighot, M. Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors. Bull Natl Res Cent 47, 134 (2023). https://doi.org/10.1186/s42269-023-01107-9

Alginate Formulations (e.g., Gaviscon®):
Form a floating “raft” or gel-like barrier on top of stomach contents, preventing reflux into the esophagus.

  • Benefit: Provides fast, physical protection without altering acid production (Kwiatek et al. 2011).
  • Limitation: Works mainly as a mechanical shield; it does not repair the lower esophageal sphincter (LES) or improve motility.

Prokinetics (e.g., metoclopramide, domperidone, itopride):
Enhance gastric emptying and improve esophageal motility.

  • Problem: Not widely available OTC in the U.S. and often limited by significant side effects, including neurological complications (Camilleri et al. 2018). Contraindicated for people with Parkinson’s, seizure disorders, history of bowel obstructions.

Natural Demulcents & Herbal OTC Remedies (e.g., deglycyrrhizinated licorice [DGL], slippery elm, aloe vera, marshmallow root):
Create a soothing coating along the esophagus and stomach lining, reducing irritation.

  • Problem: Evidence is largely anecdotal or from small clinical trials. Quality and potency vary, and they do not directly address LES dysfunction or delayed gastric emptying (Zalewski et al. 2021).

The Real Problem: Acid in the Wrong Place

All of these treatments reduce or buffer acid, but none address why acid escapes:

  • A weak or relaxed lower esophageal sphincter (LES) that fails to close properly
  • Delayed gastric emptying, leaving food in the stomach too long
  • Poor esophageal clearance, allowing acid to linger and cause damage

By lowering acid too much, conventional therapies can weaken digestion over time — since stomach acid is vital for nutrient absorption, protein breakdown, and defending against harmful bacteria.

Why Re:flux Works When Other Treatments Don’t.

Re:flux isn’t a band-aid. It’s safe for daily use and works with your body to restore balance — giving lasting relief that other treatments can’t.

Clinical Action Re:flux Antacids Blocker Alginates Prokinetics Natural Remedies
Fast Symptom Relief (slower)
Reduces/Rebalances Acid (buffers without suppression) (buffers only) (moderate)
Protects LES (Valve)
Improves Motility / Emptying Some
Safe for Long-Term Use (mineral imbalance) (nutrient malabsorption) (short-term only) (side effects, limited use) (lifestyle dependent)
Maintains Nutrient Absorption
Addresses Root Causes Partial Partial

References

  • Camilleri, Michael, Prakash Gyawali, Magnus Simrén, David A. Katzka, and Jan Tack. 2018. “Clinical Guideline: Management of Gastroparesis.” American Journal of Gastroenterology 113 (1): 60–78. https://doi.org/10.1038/ajg.2017.288.
  • Freedberg, Daniel E., Lora S. Kim, and Yuhong-Xu Yang. 2017. “The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice from the American Gastroenterological Association.” Gastroenterology 152 (4): 706–15. https://doi.org/10.1053/j.gastro.2017.01.031.
  • Ito, Tetsuo, and Robert T. Jensen. 2010. “Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium.” Current Gastroenterology Reports 12 (6): 448–57. https://doi.org/10.1007/s11894-010-0141-0.
  • Kwiatek, Marcin A., Ravinder K. Pandolfino, Peter J. Kahrilas, and John E. Pandolfino. 2011. “Alginate Therapy in Gastroesophageal Reflux Disease: Evidence for a Unique Mechanism of Action.” Diseases of the Esophagus 24 (6): 477–84. https://doi.org/10.1111/j.1442-2050.2011.01182.x.
  • Scarpignato, C., N. Pelosini, and J. M. Pooran. 2016. “Management of Rebound Acid Hypersecretion Following Withdrawal of Proton Pump Inhibitors.” Alimentary Pharmacology & Therapeutics 44 (1): 59–70. https://doi.org/10.1111/apt.13663.
  • Tytgat, Guido N. J. 2013. “Review Article: Treatments for the Symptomatic Patient with Gastro-oesophageal Reflux Disease.” Alimentary Pharmacology & Therapeutics 38 (Suppl 1): 30–38. https://doi.org/10.1111/apt.12308.
  • Zalewski, Krzysztof, Maria Białkowska, and Magdalena Sobczak. 2021. “Alternative and Complementary Therapies in Gastroesophageal Reflux Disease: A Review.” Przegla̜d Gastroenterologiczny 16 (1): 5–12. https://doi.org/10.5114/pg.2021.104141.
  • Morris, N., Nighot, M. Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors. Bull Natl Res Cent 47, 134 (2023). https://doi.org/10.1186/s42269-023-01107-9